A recent study successfully developed a monoclonal antibody targeting CD161, demonstrating that this high-affinity antibody effectively inhibits the interaction between the inhibitory receptor CD161 and its ligand CLEC2D, thereby enhancing critical T cell functions and offering potential immunotherapeutic strategies for various hematological malignancies (Alvarez Calderon et al. 2024). Here, KLRB1 is linked to hematologic disorder.